It’s funny that they are fully funded all the way into phase 2 with non dilutive funding extending the companies funds well into phase 2 and the market cap is now trading below it’s coming up cash funding pricing nothing in for how de risked the drug is heading into phase 1 and phase 2 FDA approval. AGN is looking like on any good news will become a 200-300 million dollar company on the potential of the drug.
- Forums
- ASX - By Stock
- NYR
- Ann: Significant Neuroprotection in NYR Preclinical Brain Injury
Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-186
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NYR (ASX) to my watchlist
|
|||||
Last
5.5¢ |
Change
0.001(0.92%) |
Mkt cap ! $10.02M |
Open | High | Low | Value | Volume |
5.7¢ | 5.7¢ | 5.5¢ | $597 | 10.56K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 18300 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 174265 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 24357 | 0.054 |
1 | 30003 | 0.052 |
1 | 30000 | 0.051 |
2 | 30000 | 0.050 |
1 | 100000 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 174265 | 3 |
0.058 | 248446 | 2 |
0.060 | 22000 | 2 |
0.061 | 150000 | 1 |
0.065 | 71643 | 2 |
Last trade - 15.56pm 30/08/2024 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online